#1Semaglutide
Suppresses appetite via central satiety signaling and slows gastric emptying; drove the large weight-loss effects seen in the STEP trial program.
Best peptides by research goal
Appetite, fat loss & metabolic rate · 5,480 indexed studies
Best peptides for Weight Loss & Metabolic Health
Compounds researched for effects on appetite regulation, fat mobilization, glycemic control, and metabolic rate. Spans FDA-approved incretin-based drugs with large randomized-trial evidence bases down to peptide fragments studied mainly in early-stage or discontinued trials.
This is the best-evidenced goal on VialCheck by a wide margin, largely because semaglutide and tirzepatide carry large FDA-trial literatures behind approved drugs. That volume drops off sharply outside the approved incretin class — retatrutide is still investigational, and older fragments like AOD-9604 were pursued in human trials that were ultimately discontinued for lack of effect. Read the individual compound notes before assuming volume in this goal implies safety data for a specific vendor's product.
For educational and research purposes only. Nothing here is medical advice; these compounds are not approved for human consumption outside prescription use.
Most-researched peptides
Ranked by indexed studies#2Tirzepatide
Dual GIP/GLP-1 receptor agonist; head-to-head trials show larger average weight loss than GLP-1-only agents.
#3Retatrutide
Investigational triple agonist; added glucagon-receptor activity contributes an energy-expenditure effect on top of appetite suppression. Not yet FDA-approved.
#4CJC-1295
Long-acting GHRH analog that stimulates pulsatile endogenous GH/IGF-1 release, which can support fat metabolism and lean-mass maintenance during a caloric deficit. Modest literature base.
#5AOD-9604
A modified HGH fragment engineered to isolate growth hormone's fat-mobilizing activity. Evidence is thin — its human obesity trials were discontinued for failing to beat placebo.
Frequently asked questions
Most of the literature is on incretin signalling — the GLP-1, GIP and glucagon receptors — which changes appetite, gastric emptying and, for glucagon, energy expenditure. Weight change is a downstream outcome of those effects, not a direct action on fat cells.
Study counts are PubMed search-result totals checked on September 24, 2026 and will change as new literature is indexed — the linked search always reflects the current live count. Vendor counts come from the products VialCheck currently tracks. This is a research index, not an endorsement of any compound, vendor, or use.